title: The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology.
abstract: BACKGROUND
  Neuroblastoma is the most common malignant cause of spinal compression in the pediatric population. More than 30% of patients who are impaired prior to treatment remain impaired after the completion of therapy. Those who do not improve after decompressive laminectomy may go on to develop severe delayed spinal deformities.
  
  
  METHODS
  To decrease the long term sequelae of routine neurosurgical intervention for all intraspinal extensions of neuroblastoma, the French NBL 90 Study was formulated to use chemotherapy as a first-line treatment for all nonmetastatic neuroblastomas with intraspinal extension. Neurosurgical decompression and excision was recommended only for patients demonstrating rapid neurologic deterioration.
  
  
  RESULTS
  The overall survival of the 42 patients registered was 97%. Initial neurologic impairment was present in 27 patients (64%), including 11 with paraplegia. Thirty-two patients received chemotherapy as first-line treatment. Complete regression of the intraspinal component was observed in 13 patients and partial regression of greater than 50% of the initial volume in 5 patients. Of 19 evaluable patients presenting with a neurologic deficit and treated with primary chemotherapy, recovery was completed in 11 and partial in 3. Four patients failed to recover from long-standing pretreatment paraplegia. Only one patient worsened during therapy, and recovered completely after emergent neurosurgical intervention. Seven patients underwent initial neurosurgical procedures; six had a neurologic deficit and five recovered completely, including all three who presented with acute onset of paraplegia. Three patients had extraspinal surgery as exclusive treatment. Six patients (15%) suffered severe neurologic sequelae. Only one of the patients who underwent surgery required spinal stabilization for progressive deformity, but follow-up is limited.
  
  
  CONCLUSIONS
  By treating patients with dumbbell neuroblastoma initially with chemotherapy, the authors were able to reduce the size of the intraspinal mass in 58% of patients, improve partial neurologic deficits in 92%, and avoid neurosurgical decompression in 60%. Neurologic deficits also improved in 83% of patients requiring emergent neurosurgical intervention.
authors.affiliation: Pediatric Department, Centre Hospitalier Universitaire, Hospital Michallon, Grenoble, France.
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.forename: H
authors.initials: H
authors.lastname: Rubie
authors.forename: J
authors.initials: J
authors.lastname: Michon
authors.forename: F
authors.initials: F
authors.lastname: Mechinaud
authors.forename: C
authors.initials: C
authors.lastname: Coze
authors.forename: P
authors.initials: P
authors.lastname: Chastagner
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: M
authors.initials: M
authors.lastname: Gigaud
authors.forename: J G
authors.initials: JG
authors.lastname: Passagia
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007796:Laminectomy; D008297:Male; D018365:Neoplasm, Residual / Q000601:surgery; D009447:Neuroblastoma / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D009460:Neurologic Examination; D010264:Paraplegia / Q000209:etiology; D011446:Prospective Studies; D012074:Remission Induction; D013117:Spinal Cord Compression / Q000209:etiology / Q000601:surgery; D013125:Spinal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome